Search

everythinglearnresearchcommunity

for

Search:↓

A 28-year-old male reports progress in hair regrowth using 5mg Minoxidil and 0.5mg Dutasteride, noting improvement in the crown area. Another user shares similar positive results since starting treatment in January.

A 28-year-old male, previously on dutasteride for hair loss, is considering oral minoxidil or a compounded treatment of minoxidil, finasteride, and tretinoin after noticing hairline recession. The dermatologist suggested oral minoxidil and mentioned a compounded option, but the user is unsure about its benefits compared to current treatments.

A user reported success with a once-a-day chewable pill containing Min 3mg, biotin 2.5mg, fin 1.1mg, vit B5 10mg, vit B6 2mg, and vit C 100mg for hair regrowth. They experienced no side effects and noticed healthier hair and more facial hair.

The user shared progress pictures showing hair improvement since July 2025 using a combo pill containing oral minoxidil 5mg, finasteride 1.1mg, and biotin 1mg, with no noticeable side effects. The user feels more confident and has not experienced any shedding.

The conversation is about whether to use gloves when applying 5% RU58841 to avoid systemic absorption and if washing hands with water is sufficient. Users question the concern, noting it is applied to the scalp.

A user is seeking suggestions for a custom hair lotion mix containing minoxidil, finasteride, caffeine, niacinamide, and biotin. Another user suggests adding tretinoin, topical valproate, and bimatoprost.

The user is using Minoxidil 5% with procapil spray and oral Minoxidil 2.5mg daily, and plans to add finasteride 1mg. They accidentally ordered a Minoxidil solution with finasteride 0.1% and are seeking advice on which to use.

The conversation is about using 1mg finasteride and 5% topical minoxidil for hair loss, along with a dermaroller, Alpecin caffeine shampoo, and Nizoral shampoo. Users express optimism about the potential improvement in hair density.

The user shared their 6-month progress using Dutasteride .5 daily, RU 100mg once a day, and 15 mg oral Minoxidil for hair loss. They reported visible results, no side effects, and increased body hair, despite concerns from others about the high dosage and potential health risks.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

People are discussing making their own PP405 for hair loss treatment using JLX069 and DMSO. There is skepticism about the safety and effectiveness of this homemade solution, with some users expressing concerns about potential risks.

A user ordered a compounded medication from Musely containing Dutasteride, Minoxidil, and other vitamins, expressing concerns about its contents and effectiveness. Another user shared their experience with side effects but noted hair regrowth, while adjusting the dosage to reduce symptoms.

Combining Minoxidil with Finasteride or RU58841 may cause interference, irritation, or reduced absorption. It might be better to apply one topical at a time and wait an hour before applying another.

Avoid home-compounding topical minoxidil due to potential risks and complications. Use proper equipment and techniques to prevent aerosolization and ensure effective dissolution.

People are discussing hair loss treatments, including pyrilutamide, minoxidil, dutasteride, alfatradiol, and bimatoprost. Users share their experiences and side effects, noting that pyrilutamide is considered more effective and safer than RU58841.

VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.

The user is considering two hair loss treatments: Minoxidilmax Maxogen-x, which contains Minoxidil, Finasteride, Azelaic Acid, ABN Complex, Retinoic Acid, Fluocinolone, and Caffeine, and Morr-F, which contains only Minoxidil and Finasteride. They are asking for others' experiences with these brands.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

Sprocketshead asks if pyrilutamide can be applied with minoxidil, and inquires about its consistency and odor. They want to know if it's more high maintenance than topical minoxidil.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

The user is considering adding a topical treatment to their current regimen of finasteride and oral minoxidil to protect their temple area, with options like piro, RU58841, or topical finasteride or dutasteride. They are advised against overcomplicating their treatment, but another user suggests a topical with 8% minoxidil/dutasteride for better results.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

Kintor apologized for using misleading images in their advertisements and promised stricter review processes. They are also considering developing a topical dutasteride formulation.

The conversation is about using RU58841 for hair loss, discussing the stability of the powder form and the need for a carrier solution like KB or PG + ethanol. The user is advised to mix RU58841 with stemoxydine and store it properly, while also considering safety precautions.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A joke about creating a hair loss treatment in the kitchen, with replies encouraging more jokes.

Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.

The conversation is about sourcing RU58841 for hair loss treatment, with a focus on finding reputable sellers. The user plans to use 10mg/ml daily, split into two doses, prioritizing quality over price.